DeepMed Research

CARDURION PHARMACEUTICALS, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effectiveness of Repeat-dose CRD-4730 in Participants with CPVT

Phase 2

Not yet recruiting

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions: Drug: CRD-4730
Drug: Placebo

First Posted Date: 2024-10-26

Last Posted Date: 2024-11-01

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT06658899

Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

Phase 2

Recruiting

Conditions: Heart Failure Preserved Ejection Fraction
Cardiovascular Diseases
Heart Diseases
Heart Failure

Interventions: Drug: Tovinontrine (CRD-750
Drug: Placebo

First Posted Date: 2024-01-22

Last Posted Date: 2025-05-23

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 240

Registration Number: NCT06215586

Locations: 🇬🇧
Cardurion Investigative Site, Southampton, United Kingdom
🇩🇪
Cardurion Investigational Site, Dresden, Germany

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

Phase 2

Recruiting

Conditions: Heart Failure
Heart Failure With Reduced Ejection Fraction
Cardiovascular Diseases
Heart Diseases

Interventions: Drug: Tovinontrine (CRD-750)
Drug: Placebo

First Posted Date: 2024-01-22

Last Posted Date: 2025-05-23

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 400

Registration Number: NCT06215911

Locations: 🇬🇧
Cardurion Investigative Site, Southampton, United Kingdom
🇧🇪
Cardurion Investigational Site, Brugge, Belgium
🇬🇪
Cardurion Investigative Site 2, Tbilisi, Georgia

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Phase 2

Recruiting

Conditions: CPVT1
Heart Defects, Congenital
Heart Diseases
Ventricular Tachycardia

Interventions: Drug: CRD-4730
Drug: Placebo

First Posted Date: 2023-08-22

Last Posted Date: 2025-01-20

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT06005428

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Cleveland Clinic Children&#39;s Hospital, Cleveland, Ohio, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 8 locations

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Phase 1

Completed

Conditions: Pharmacokinetics
Cardiovascular Diseases
Clinical Pharmacology
Heart Failure

Interventions: Drug: CRD-740
Drug: Itraconazole

First Posted Date: 2022-06-29

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT05437094

Locations: 🇺🇸
Cardurion Investigative Site, Dallas, Texas, United States

Effectiveness of CRD-740 in Heart Failure

Phase 2

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Cardiovascular Diseases
Heart Failure
Heart Diseases

Interventions: Drug: CRD-740
Drug: Placebo

First Posted Date: 2022-06-08

Last Posted Date: 2024-12-19

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT05409183

Locations: 🇬🇧
Cardurion Investigative Site, Stockton-on-Tees, United Kingdom

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

Phase 2

Withdrawn

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Other: IMR-687 Placebo
Drug: IMR-687

First Posted Date: 2022-04-05

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Registration Number: NCT05312021

A Study of IMR-687 in Subjects With Sickle Cell Disease

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2020-07-16

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 115

Registration Number: NCT04474314

Locations: 🇬🇧
Guy's and Saint Thomas' NHS Foundation Trust, London, England, United Kingdom
🇬🇧
King's College Hospital NHS Foundation Trust, London, England, United Kingdom
🇺🇬
Uganda Cancer Institute, Kampala, Uganda

and more 46 locations

A Study of IMR-687 in Subjects With Beta Thalassemia

Phase 2

Terminated

Conditions: β Thalassemia

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2020-06-02

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 122

Registration Number: NCT04411082

Locations: 🇲🇾
Hospital Sultanah Aminah Johor Bharu, Johor Bahru, Johor, Malaysia
🇩🇰
Herlev Hospital, Herlev, Hovedstaden, Denmark
🇫🇷
Hôpital Edouard Herriot, Lyon Cedex 03, Rhone, France

and more 33 locations

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2018-01-17

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 100

Registration Number: NCT03401112

Locations: 🇺🇸
Loretto Hospital, Chicago, Illinois, United States
🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy